HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, Inc. (NRXP), announced signing a non-binding Term Sheet for non-dilutive, nonconvertible debt acquisition funding of its first interventional psychiatry clinics, together with the signing of a Term Sheet for five currently operational clinics in the Western United States.
Jonathan Javitt and Matthew Duffy, Co-CEOs of HOPE Therapeutics, said: "These clinics, and others under review, are planned to provide the foundation for a network generating revenue of approximately $100 million annually in the coming year."
For More Such Health News, visit rttnews.com.
For comments and feedback: editorial@rttnews.com